Cellectar Biosciences Shares Up 7.1% Premarket After Co. Announced Encouraging Results From CLR 131 Phase 2 Clinical Trial With Diffuse Large B-Cell Lymphoma Patients, Overall Response Rate Was 33% With Tumor Reductions Ranging From 60% To Over 90%
Benzinga Newsdesk